

# Drug Repositioning Approaches and Applications for Neurotherapeutics

Edited by  
Joel Dudley  
Laura Berliocchi



CRC Press  
Taylor & Francis Group

**FRONTIERS IN NEUROTHERAPEUTICS**

SERIES EDITORS: DIANA AMANTEA LAURA BERLIOCCHI ROSSELLA RUSSO

# Drug Repositioning

## Approaches and Applications for Neurotherapeutics

Edited by  
Joel Dudley and Laura Berliocchi



**CRC Press**

Taylor & Francis Group

Boca Raton London New York

---

CRC Press is an imprint of the  
Taylor & Francis Group, an **informa** business

CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742

©2017 by Taylor & Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

International Standard Book Number-13: 978-1-4822-2083-4 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

---

#### Library of Congress Cataloging-in-Publication Data

---

Names: Dudley, Joel T. | Berliocchi, Laura.  
Title: Drug Repositioning: Approaches and Applications for Neurotherapeutics / [edited by] Joel Dudley and Laura Berliocchi.  
Description: Boca Raton: CRC Press, [2017] | Series: Frontiers in Neurotherapeutics series | Includes bibliographical references and index.  
Identifiers: LCCN 2016059349 | ISBN 9781482220834 (hardback: alk. paper) | ISBN 9781315373669 (ebook)  
Subjects: LCSH: Drug development. | Neuropharmacology.  
Classification: LCC RM301.25 .D786148 2017 | DDC 615.1/9--dc23  
LC record available at <https://lcn.loc.gov/2016059349>

---

Visit the Taylor & Francis Web site at  
<http://www.taylorandfrancis.com>

and the CRC Press Web site at  
<http://www.crcpress.com>



Printed and bound in Great Britain by  
TJ International Ltd, Padstow, Cornwall

# Drug Repositioning

Approaches and Applications for  
Neurotherapeutics

# FRONTIERS IN NEUROTHERAPEUTICS SERIES

## *Series Editors*

Diana Amantea, Laura Berliocchi, and Rossella Russo

## **Drug Repositioning: Approaches and Applications for Neurotherapeutics**

*Joel Dudley*, Mount Sinai School of Medicine, New York, New York, USA

*Laura Berliocchi*, Magna Græcia University, Catanzaro, Italy

## **Mapping of Nervous System Diseases via MicroRNAs**

*Christian Barbato*, Institute of Cell Biology and Neurobiology (IBCN), Rome, Italy

*Francesca Ruberti*, Institute of Cell Biology and Neurobiology (IBCN), Rome, Italy

## **Rational Basis for Clinical Translation in Stroke Therapy**

*Giuseppe Micieli*, IRCCS, Pavia, Italy

*Diana Amantea*, University of Calabria, Rende, Italy

---

# Preface

A better understanding of many nervous system disorders and their effective treatment represents an important scientific challenge and an increasing concern for health systems worldwide, due to the chronic nature of some of these conditions and their high incidence especially in the increasing aging population. In spite of significant financial and professional investments, and great advances made during the past two decades, the fundamental etiology and pathophysiology of many diseases affecting the nervous system remain unclear, and effective disease-modifying therapies are still lacking. The reasons for such a failure in developing new effective therapeutics for nervous system disorders are several and of different nature. The intricate biology of the nervous system itself, together with the complexity and slow progression of these specific pathologies, made it difficult to understand the basic disease mechanisms and to identify appropriate end points and biomarkers, essential in achieving an accurate stratification of patients' populations. Indeed, patients' heterogeneity, lack of reliable biomarkers for both diagnosis and treatment, and slow progression are some of the factors responsible for the failure of many clinical trials. Furthermore, limitations related to the uncertain predictive validity of animal models seem to have interfered with the successful identification of safe and/or effective new candidate drugs, and contributed to the high rate of late-stage clinical trial failures, for instance in the case of drugs acting on the central nervous system.

In addition to the existing biological reasons, regulatory barriers seem to have contributed to make *de novo* drug discovery and development for nervous system diseases a lengthy, costly, and risky process. Although this is particularly true for drug development in the field of neuroscience, in recent years it has become more and more clear that, in general, the whole traditional paradigm of R&D needed some rethinking. Over the last decade, increasing pharma R&D costs were not paralleled by increased productivity. On the contrary, the relationship between the investments to develop new innovative drugs and the outcome in terms of the resulting medical and financial benefits dramatically decreased, and only very few new drugs were approved.

Among the possible alternative approaches to *de novo* drug discovery, drug repositioning seems to be one of the most promising strategies to develop therapeutic options for currently unmet medical needs. Drug repositioning or repurposing or reprofiling (the terms are sometimes used interchangeably) refers to a designed way to identify new applications for existing drugs, at any stage of their long developmental or clinical path. This also includes drugs that have been shown to be safe but not effective for the indication they were originally developed for or, to the extreme, drugs investigated but not further developed or even removed from the market for safety reasons (drug rescue).

Thanks to the most recent advancements in technologies, including *in vitro/in vivo* screening approaches and computational tools such as bioinformatics, chemoinformatics, network biology, and system biology, the drug repositioning concept has flourished and moved from casual discoveries to targeted strategies.

Repositioning shows several advantages over traditional *de novo* drug discovery, such as reduced development costs and shorter time to approval and launch, and is emerging as a particularly attractive approach for several pathologies including rare and neglected diseases. Although with some challenges, the recovery of failed compounds for new indications clearly represents an interesting business opportunity for the industry, as also shown by the creation of *ad hoc* partnerships between big pharma, academia, and governments. Also from a social standpoint, conveying existing data and knowledge toward new therapeutic applications stands as a highly ethical way to maximize the use of patient information, and several nonprofit organizations have launched programs specifically aimed to support drug repurposing projects and initiatives.

It is clear that collaboration between different entities is key to the success of this attractive and complex new strategy in improving and accelerating therapeutic development for nervous system disorders.

Renowned experts from different settings (academia, industry, nonprofit organizations) will discuss all these aspects in the present volume of the series *Frontiers in Neurotherapeutics*. The book aims to provide an overview of drug repositioning applications specific to neurotherapeutics and is organized in three sections, each composed of several chapters. *Section I* introduces the concept and rationale of drug repositioning, illustrates the different possible challenges in repurposing by analyzing the cases of Alzheimer's and Parkinson's diseases, and describes the contribution of nonprofit research organizations. *Section II* illustrates the evolution of drug repositioning from a serendipitous advance to a precise strategy, providing some examples of techniques and tools used for the identification of new applications for existing compounds. *Section III* focuses on drug repositioning relevance specifically for nervous system diseases, providing some historical examples and analyzing in individual chapters the status of some of the main nervous system conditions (Alzheimer's, Parkinson's, and Huntington's diseases; amyotrophic lateral sclerosis; spinal muscular atrophy; ischemic stroke; and psychiatric disorders).

We thank all the authors for their participation and their valuable contributions and the reviewers for their critical comments. We are particularly grateful to Hilary LaFoe for her constant support, to Natasha Hallard for her skilled help, and to all CRC Press and Taylor & Francis Group staff for their professional assistance during all phases of book production.

---

# Editors

**Dr. Joel Dudley** is associate professor of genetics and genomic sciences and director of biomedical informatics at Mount Sinai School of Medicine, New York (NY, USA). Prior to Mount Sinai, he held positions as cofounder and director of informatics at NuMedii, Inc., and consulting professor of systems medicine in the Department of Pediatrics at Stanford University School of Medicine (CA, USA), where he participated in leading research to incorporate genome sequencing into clinical practice. Dr. Dudley's current research is focused toward solving key problems in genomics and precision medicine through the development and application of translational and biomedical informatics methodologies. His publications cover the areas of bioinformatics, genomic medicine, personal and clinical genomics, as well as drug and biomarker discovery. He received a BS in microbiology from Arizona State University and an MS and a PhD in biomedical informatics from Stanford University School of Medicine (CA, USA).

**Dr. Laura Berliocchi** is associate professor of pharmacology at the Department of Health Sciences, Magna Græcia University (Catanzaro, Italy). She is leading the Pain Unit at the Center of Preclinical and Translational Pharmacology (University of Calabria, Italy), whose research activity is focused on a better understanding of the neurobiology of pain for more effective clinical treatments. Her latest research activity is focused on the role of autophagy in neuronal dysfunction and on the identification of new strategies for pain management. She received a BSc (Hons) in biology from the University of Rome "Tor Vergata" (Italy), a specialization degree in biotechnologies from the same university, and a PhD in molecular toxicology from the University of Konstanz (Germany). She was a research associate at the Medical Research Council (MRC; Leicester, UK), working on the effects of synaptic and axonal damage on neuronal function and survival, then a London Pain Consortium (LPC) senior research fellow and a scientific visitor at University College London (UCL; London, UK), where she trained in experimental models of pain and worked on mechanisms of pain control. She is a *Deutscher Akademischer Austauschdienst* (DAAD) alumna.



---

# Contributors

**Cecilio Álamo**

Department of Biomedical Sciences  
(Pharmacology Area)  
University of Alcalá  
Madrid, Spain

**Diana Amantea**

Department of Pharmacy, Health and  
Nutritional Sciences  
University of Calabria  
Rende, Italy

**Giulia Ambrosi**

Center for Research in  
Neurodegenerative Diseases  
Casimiro Mondino National  
Neurological Institute  
Pavia, Italy

**Christos Andronis**

Biovista Inc.  
Charlottesville, Virginia

**Giacinto Bagetta**

Department of Pharmacy, Health and  
Nutritional Sciences  
University of Calabria  
Rende, Italy

**Fabio Blandini**

Center for Research in  
Neurodegenerative Diseases  
Casimiro Mondino National  
Neurological Institute  
Pavia, Italy

**Bruce Bloom**

Cures within Reach  
Chicago, Illinois

**Aleksandra Caban**

Creativ-Ceutical  
Kraków, Poland

**David Cavalla**

Numedicus Limited  
Cambridge, United Kingdom

**Silvia Cerri**

Center for Research in  
Neurodegenerative Diseases  
Casimiro Mondino National  
Neurological Institute  
Pavia, Italy

**Alexander W. Charney**

Department of Neuroscience  
and  
Department of Psychiatry  
Icahn School of Medicine at Mount  
Sinai  
New York, New York

**Dennis S. Charney**

Department of Psychiatry  
Icahn School of Medicine at Mount  
Sinai  
New York, New York

**John R. Ciallella**

Melior Discovery Inc.  
Exton, Pennsylvania

**Spyros N. Deftereos**

Biovista Inc.  
Charlottesville, Virginia

**Maria P. del Castillo-Frias**

Manchester Institute of Biotechnology  
The University of Manchester  
Manchester, United Kingdom

**Andrew J. Doig**

Manchester Institute of Biotechnology  
The University of Manchester  
Manchester, United Kingdom

**Alba Esposito**

Department of Neuroscience,  
Reproductive and  
Odontostomatological Sciences  
“Federico II” University of Naples  
Naples, Italy

**Faraz Farooq**

Molecular Biomedicine Program  
Children’s Hospital of Eastern Ontario  
Research Institute  
Ottawa, Ontario, Canada

and

Mathematics & Science Department  
Emirates College for Advanced  
Education  
Abu Dhabi, United Arab Emirates

**Francesca Romana Fusco**

Laboratory of Neuroanatomy  
Santa Lucia Foundation  
Rome, Italy

**Silvia E. García-Ramos**

Hospital Pharmacy Service  
Principe de Asturias University Hospital  
Madrid, Spain

**Szymon Jarosławski**

Public Health Department  
Aix-Marseille University  
Marseille, France

**Anna Kapuśniak**

Creativ-Ceutical  
Kraków, Poland

**Eftychia Lekka**

Biovista Inc.  
Charlottesville, Virginia

**Christopher A. Lipinski**

Melior Discovery Inc.  
Exton, Pennsylvania

**Francisco López-Muñoz**

Faculty of Health Sciences and Chair of  
Genomic Medicine  
Camilo José Cela University  
and  
Faculty of Medicine and Health  
Sciences  
University of Alcalá  
and  
Neuropsychopharmacology Unit  
Hospital 12 de Octubre Research  
Institute (i+12)  
Madrid, Spain

**Christine M. Macolino-Kane**

Melior Discovery Inc.  
Exton, Pennsylvania

**Hermann Mucke**

H.M. Pharma Consultancy  
Vienna, Austria

**Francesco Napolitano**

Systems and Synthetic Biology  
Laboratory  
Telethon Institute of Genetics and  
Medicine  
Pozzuoli, Italy

**Nichole Orr-Burks**

Department of Infectious Disease  
University of Georgia  
Athens, Georgia

**Emanuela Paldino**

Laboratory of Neuroanatomy  
Santa Lucia Foundation  
Rome, Italy

**Andreas Persidis**

Biovista Inc.  
Charlottesville, Virginia

**Aris Persidis**

Biovista Inc.  
Charlottesville, Virginia

**Olivia Perwitasari**

Department of Infectious Disease  
University of Georgia  
Athens, Georgia

**Tiziana Petrozziello**

Department of Neuroscience,  
Reproductive and  
Odontostomatological Sciences  
“Federico II” University of Naples  
Naples, Italy

**Andrew G. Reaume**

Melior Discovery Inc.  
Exton, Pennsylvania

**Cecile Rémuzat**

Creativ-Ceutical  
Paris, France

**Douglas M. Ruderfer**

Department of Medicine, Psychiatry  
and Biomedical Informatics  
Vanderbilt University School of Medicine  
Nashville, Tennessee

**Joseph R. Scarpa**

Department of Genetics and Genomic  
Sciences  
Icahn School of Medicine at Mount Sinai  
New York, New York

**Agnese Secondo**

Department of Neuroscience,  
Reproductive and  
Odontostomatological Sciences  
“Federico II” University of Naples  
Naples, Italy

**Byoung-Shik Shim**

Immunology and Microbial Sciences  
The Scripps Research Institute  
Jupiter, Florida

**Valentina Tedeschi**

Department of Neuroscience,  
Reproductive and  
Odontostomatological Sciences  
“Federico II” University of Naples  
Naples, Italy

**Mondher Toumi**

Public Health Department  
Aix-Marseille University  
Marseille, France

**Ralph A. Tripp**

Department of Infectious Disease  
University of Georgia  
Athens, Georgia

**Vassilis Virvillis**

Biovista Inc.  
Charlottesville, Virginia

---

# Contents

Preface.....ix  
Editors .....xi  
Contributors .....xiii

**SECTION I    *The Rationale and Economics  
of Drug Repositioning***

**Chapter 1**    Scientific and Commercial Value of Drug Repurposing ..... 3  
                  *David Cavalla*

**Chapter 2**    Repurposing for Alzheimer’s and Parkinson’s Diseases: The  
                  Ideas, the Pipeline, the Successes, and the Disappointments ..... 23  
                  *Hermann Mucke*

**Chapter 3**    Contribution of Not-for-Profit Organizations to Drug Repurposing .... 41  
                  *Bruce Bloom*

**SECTION II    *Repositioning Approaches and  
Technologies: From Serendipity to  
Systematic and Rational Strategies***

**Chapter 4**    Systematic Drug Repositioning..... 61  
                  *Spyros N. Deftereos, Aris Persidis, Andreas Persidis,  
                  Eftychia Lekka, Christos Andronis, and Vassilis Virvillis*

**Chapter 5**    Technical Tools for Computational Drug Repositioning..... 83  
                  *Francesco Napolitano*

**Chapter 6**    RNAi Screening toward Therapeutic Drug Repurposing ..... 105  
                  *Nichole Orr-Burks, Byoung-Shik Shim, Olivia Perwitasari,  
                  and Ralph A. Tripp*

<b>Chapter 7</b>	Phenotypic Screening .....	121
	<i>Christine M. Macolino-Kane, John R. Ciallella, Christopher A. Lipinski, and Andrew G. Reaume</i>	

### **SECTION III    Drug Repositioning for Nervous System Diseases**

<b>Chapter 8</b>	A Case Study: Chlorpromazine .....	147
	<i>Francisco López-Muñoz, Cecilio Álamo, and Silvia E. García-Ramos</i>	
<b>Chapter 9</b>	Drug Repurposing for Central Nervous System Disorders: A Pillar of New Drug Discovery .....	169
	<i>Mondher Toumi, Aleksandra Caban, Anna Kapuśniak, Szymon Jarostawski, and Cecile Rémuzat</i>	
<b>Chapter 10</b>	Repurposing Opportunities for Parkinson's Disease Therapies .....	177
	<i>Giulia Ambrosi, Silvia Cerri, and Fabio Blandini</i>	
<b>Chapter 11</b>	Drug Candidates for Repositioning in Alzheimer's Disease .....	201
	<i>Maria P. del Castillo-Frias and Andrew J. Doig</i>	
<b>Chapter 12</b>	Promising Candidates for Drug Repurposing in Huntington's Disease.....	221
	<i>Francesca Romana Fusco and Emanuela Paldino</i>	
<b>Chapter 13</b>	Drug Repositioning Opportunities in Psychiatry .....	241
	<i>Alexander W. Charney, Joseph R. Scarpa, Douglas M. Ruderfer, and Dennis S. Charney</i>	
<b>Chapter 14</b>	Pharmacology of Amyotrophic Lateral Sclerosis: Old Strategies and New Perspectives .....	261
	<i>Tiziana Petrozziello, Valentina Tedeschi, Alba Esposito, and Agnese Secondo</i>	

**Chapter 15** Repositioning Clinic-Ready Compounds for the Treatment  
of Spinal Muscular Atrophy .....275  
*Faraz Farooq*

**Chapter 16** Rescuing Ischemic Brain Injury by Targeting the Immune  
Response through Repositioned Drugs .....287  
*Diana Amantea and Giacinto Bagetta*

**Index**.....303

# *Section I*

---

## *The Rationale and Economics of Drug Repositioning*





---

# 1 Scientific and Commercial Value of Drug Repurposing

David Cavalla

## CONTENTS

1.1	Introduction .....	3
1.2	Case Histories .....	4
1.3	Advantages of Drug Repurposing .....	8
1.3.1	Attritional Risk .....	8
1.3.2	Cost .....	10
1.3.3	Time .....	11
1.4	Disadvantages .....	12
1.4.1	Off-Label Medicine .....	13
1.5	Variants .....	14
1.5.1	Repurposing of Generic Drugs .....	15
1.5.2	Repurposing of Abandoned Assets .....	15
1.6	Off-Target <i>versus</i> On-Target .....	16
1.6.1	Rare Diseases .....	17
1.7	Conclusion .....	19
	References.....	19

## 1.1 INTRODUCTION

Drug repurposing is a directed strategy to identify new uses for existing drugs, to be embarked upon at any stage in their developmental or clinical life. For pharmaceutical R&D, the benefits are clear: alongside reduced risk of developmental failure, there is demonstrable reduced cost and time of development. While historically many examples of repurposing arose from serendipitous clinical findings, modern repurposing has other skills in its toolbox; it may also derive from literature-based methods, deliberate *in vitro* or *in vivo* screening exercises, or *in silico* computational techniques to predict functionality based on a drug's gene expression effects, interaction profile, or chemical structure.

From the earliest times of medicine, doctors have sought further uses for available treatments. Traditional folk medicines are often proposed for the treatment of a bewilderingly wide range of purposes. The keystone in the process of new uses for existing drugs is the physician; they approach the issue using the principle of "clinical relatedness," whereby if a drug is useful for condition A, it is likely to be useful for a related condition B.